Literature DB >> 23991296

C-reactive protein levels are raised in stable Chronic obstructive pulmonary disease patients independent of smoking behavior and biomass exposure.

Funda Aksu1, Nermin Capan, Kurtuluş Aksu, Ruhsar Ofluoğlu, Sema Canbakan, Bünyamin Yavuz, Kadir Okhan Akin.   

Abstract

BACKGROUND: The aim of this case control study is to assess the relationship between serum C-reactive protein (CRP) levels and well-known clinical parameters in Chronic obstructive pulmonary disease (COPD) considering the impact of smoking behavior, biomass exposure and accompanying clinical entities, namely pulmonary hypertension, systemic hypertension and diabetes mellitus.
METHODS: Spirometry, echocardiography, arterial oxygen saturation (SpO2) measurements, BODE scores and serum CRP levels were investigated in stable COPD patients. Associations between CRP levels and clinical parameters were evaluated.
RESULTS: CRP levels are significantly higher in COPD patients than in healthy controls. CRP levels were not significantly different between COPD patients treated with inhaled corticosteroids and those not treated. CRP levels significantly correlated with age, FEV1% predicted, FVC% predicted, SpO2, MMRC, 6 minute walk distance, BODE scores and haemoglobin levels. In multivariate analysis BODE scores and concomitant systemic hypertension manifested the strongest association with CRP levels. CRP levels in COPD patients with and without pulmonary hypertension were significantly different. CRP levels did not differ significantly according to smoking status or biomass exposure, moreover COPD cases due to biomass exposure who never smoked also had higher CRP levels compared to healthy controls.
CONCLUSIONS: Systemic inflammation is inherent to COPD independent of ever-smoking status and correlates with disease severity, concomitant systemic hypertension and pulmonary hypertension.

Entities:  

Keywords:  Biomass; C-reactive protein (CRP); chronic obstructive pulmonary disease (COPD); pulmonary artery pressure; smoking behaviour

Year:  2013        PMID: 23991296      PMCID: PMC3755654          DOI: 10.3978/j.issn.2072-1439.2013.06.27

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  28 in total

1.  Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.

Authors:  M A Albert; E Danielson; N Rifai; P M Ridker
Journal:  JAMA       Date:  2001-07-04       Impact factor: 56.272

2.  Does exercise reduce inflammation? Physical activity and C-reactive protein among U.S. adults.

Authors:  Earl S Ford
Journal:  Epidemiology       Date:  2002-09       Impact factor: 4.822

Review 3.  Local and systemic inflammation in chronic obstructive pulmonary disease.

Authors:  Emiel F M Wouters
Journal:  Proc Am Thorac Soc       Date:  2005

4.  Is systemic inflammation responsible for pulmonary hypertension in COPD?

Authors:  Don D Sin; S F Paul Man
Journal:  Chest       Date:  2006-08       Impact factor: 9.410

5.  Biomarkers in COPD: are we there yet?

Authors:  Don D Sin; S F Paul Man
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

6.  Systemic inflammation in patients with COPD and pulmonary hypertension.

Authors:  Pavol Joppa; Darina Petrasova; Branislav Stancak; Ruzena Tkacova
Journal:  Chest       Date:  2006-08       Impact factor: 9.410

7.  C-reactive protein levels and clinically important predictive outcomes in stable COPD patients.

Authors:  J P de Torres; E Cordoba-Lanus; C López-Aguilar; M Muros de Fuentes; A Montejo de Garcini; A Aguirre-Jaime; B R Celli; C Casanova
Journal:  Eur Respir J       Date:  2006-02-02       Impact factor: 16.671

8.  Prognostic value of C-reactive protein in chronic obstructive pulmonary disease.

Authors:  Massimo Miniati; Simonetta Monti; Matteo Bottai; Franca Cocci; Edo Fornai; Valter Lubrano
Journal:  Intern Emerg Med       Date:  2011-01-20       Impact factor: 3.397

Review 9.  Diagnosis and differential assessment of pulmonary arterial hypertension.

Authors:  Robyn J Barst; Michael McGoon; Adam Torbicki; Olivier Sitbon; Michael J Krowka; Horst Olschewski; Sean Gaine
Journal:  J Am Coll Cardiol       Date:  2004-06-16       Impact factor: 24.094

10.  Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease.

Authors:  Don D Sin; Paige Lacy; Ernest York; S F Paul Man
Journal:  Am J Respir Crit Care Med       Date:  2004-06-30       Impact factor: 21.405

View more
  17 in total

Review 1.  Clinical Characteristics of Patients With Biomass Smoke-Associated COPD and Chronic Bronchitis, 2004-2014.

Authors:  Rogelio Pérez-Padilla; Alejandra Ramirez-Venegas; Raul Sansores-Martinez
Journal:  Chronic Obstr Pulm Dis       Date:  2014-05-06

2.  Cross-sectional associations of pulmonary function with systemic inflammation and oxidative stress in individuals with chronic spinal cord injury.

Authors:  Jaime E Hart; Leslie Morse; Carlos G Tun; Robert Brown; Eric Garshick
Journal:  J Spinal Cord Med       Date:  2015-07-16       Impact factor: 1.985

Review 3.  Therapeutic approaches targeting molecular signaling pathways common to diabetes, lung diseases and cancer.

Authors:  Rajeswari Raguraman; Akhil Srivastava; Anupama Munshi; Rajagopal Ramesh
Journal:  Adv Drug Deliv Rev       Date:  2021-08-08       Impact factor: 15.470

4.  FEV1 inversely correlates with metalloproteinases 1, 7, 9 and CRP in COPD by biomass smoke exposure.

Authors:  Martha Montaño; Raul H Sansores; Carina Becerril; Jose Cisneros; Georgina González-Avila; Bettina Sommer; Leticia Ochoa; Iliana Herrera; Alejandra Ramírez-Venegas; Carlos Ramos
Journal:  Respir Res       Date:  2014-06-30

5.  Low FEV1, smoking history, and obesity are factors associated with oxygen saturation decrease in an adult population cohort.

Authors:  Monica Linea Vold; Ulf Aasebø; Hasse Melbye
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-10-21

6.  FEV1 and FVC and systemic inflammation in a spinal cord injury cohort.

Authors:  Jaime E Hart; Rebekah Goldstein; Palak Walia; Merilee Teylan; Antonio Lazzari; Carlos G Tun; Eric Garshick
Journal:  BMC Pulm Med       Date:  2017-08-15       Impact factor: 3.317

7.  Comparison of Immediate and Sequential Withdrawal of a Systemic Glucocorticoid in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Multicenter, Randomized, Double-Blind, Parallel-Controlled, Open-Label Study.

Authors:  Ling Zhou; Yuanyuan Fang; Wei Liu; Jianchu Zhang; Yingnan Wang; Sheng Xie; Minhua Zhong; Zhengyan Wang; Guangcai Li; Hongyan Ai; Hongrong Guo; Fanjun Zeng; Wei Xiao; Chenghong Li; Yi Hu; Yijun Tang; Huiguo Liu
Journal:  Front Mol Biosci       Date:  2021-05-20

8.  Incidence and risk factors of atrial fibrillation in Asian COPD patients.

Authors:  Kuang-Ming Liao; Chung-Yu Chen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-08-23

9.  C-Reactive Protein Concentrations Among Crop and Dairy Farmers with Stable Chronic Obstructive Pulmonary Disease.

Authors:  Saso Stoleski; Jordan Minov; Jovanka Karadzinska-Bislimovska; Dragan Mijakoski; Lütfiye Tutkun
Journal:  Open Access Maced J Med Sci       Date:  2017-09-09

10.  Smoking exposure, loss of forced expiratory volume in one second and the risk of lung cancer among patients with malignant disease who present with cardiac or pulmonary symptoms: a cross-sectional study.

Authors:  Siegfried Wieshammer; Jens Dreyhaupt
Journal:  Tob Induc Dis       Date:  2017-03-09       Impact factor: 2.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.